Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Cancer Immunity Cycle Could Inform Development of Novel Immune Therapies in RCC

November 11th 2023

Further understanding of the cancer immunity cycle could drive the development of novel immune therapies for patients with renal cell carcinoma.

Treatment Decisions in RCC Could Be Aided by ctDNA

November 11th 2023

Decisions regarding the intensification or de-escalation of treatment, particularly with immunotherapy and TKIs, for patients with renal cell carcinoma could be aided by circulating tumor DNA.

Dr Ramnaraign on Retrospective Data For irAEs in Older Patients With Kidney Cancer

November 11th 2023

Brian H. Ramnaraign, MD, discusses findings from a single-institution review of the incidence of immunotherapy-related toxicities in older patients with kidney cancer.

Dr Tan on the Potential Utility of ctDNA in RCC

November 11th 2023

Alan Tan, MD, discusses the ongoing investigation and potential utility of circulating tumor DNA in patients with renal cell carcinoma.

LITESPARK-013 Data Support RP2D of Belzutifan as Standard Option in Advanced ccRCC

November 11th 2023

Administration of the hypoxia-inducible factor–2α inhibitor belzutifan (Welireg) at the recommended phase 2 dose of 120 mg daily produced comparable toxicities and efficacy outcomes to that of a daily 200-mg dose of the agent in patients with advanced clear cell renal cell carcinoma.

Dr Zakharia on Real-World Outcomes With First-Line Axitinib Plus Pembrolizumab in RCC

November 11th 2023

Yousef Zakharia, MD, discusses the real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma based on International Metastatic RCC Database Consortium risk score.

Zanzalintinib Continues to Elicit Efficacy With Tolerability in Advanced ccRCC

November 10th 2023

Treatment with zanzalintinib monotherapy produced antitumor activity and was well tolerated in patients with previously treated advanced clear cell renal cell carcinoma.

Considering the Data Behind Belzutifan's Approval in VHL Disease–Associated Cancers

November 10th 2023

Jaleh Fallah, MD, discusses the FDA's evaluation of data from the phase 2 LITESPARK-004 trial, which supported the approval of belzutifan in von Hippel-Lindau–associated cancers.

Dr Pal on Outcomes With the Use of Zanzalintinib in Relapsed/Refractory ccRCC

November 10th 2023

Sumanta Kumar Pal, MD, FASCO, discusses outcomes with the use of zanzalintinib in patients with relapsed/refractory clear cell renal cell carcinoma.

Dr Braun on the Clinical Implications of the CONTACT-03 Trial in RCC

November 10th 2023

David Braun, MD, PhD, discusses the findings from the phase 3 CONTACT-03 trial investigating immunotherapy rechallenge in patients with renal cell carcinoma and the implications of these findings on the RCC treatment paradigm.

Treatments for Translocation RCC Require Novel Therapeutic Targets

November 10th 2023

Immune checkpoint inhibitors have been associated with improved outcomes for patients with metastatic translocation renal cell carcinoma; however, novel therapies and therapeutic targets are needed for patients within this histologic subset.

Dr Henderson on Incorporating Immunotherapy Agents into Practice in Bladder Cancer

November 6th 2023

R. Jonathan Henderson, MD, discusses incorporating immunotherapy agents into practice in patients with bladder cancer.

Ongoing Research Aims to Enhance Radiotherapy Techniques in Prostate Cancer

November 2nd 2023

Daniel Spratt, MD, discusses the expanded role of radiation therapy for the treatment of patients with prostate cancer, delves into the optimal approach for using radiation in tandem with hormonal therapy for these patients, and highlights ongoing research focused on minimizing adverse effects associated with radiotherapy.

Adjuvant Pembrolizumab Improves OS in Select Patients With RCC After Nephrectomy

November 1st 2023

Adjuvant treatment with pembrolizumab significantly improved overall survival vs placebo in patients with renal cell carcinoma at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions, meeting a key secondary end point of the phase 3 KEYNOTE-564 trial.

Overview on Advanced RCC: Epidemiology, Presentation, and Risk Stratification

October 30th 2023

Explore statistics behind and possible patient presentations of advanced renal cell carcinoma (RCC), with insight into IMDC risk stratification that may influence treatment strategies and outcomes.

Dr Choueiri on the Utility of Belzutifan/Cabozantinib in Advanced ccRCC

October 27th 2023

Toni K. Choueiri, MD, discusses findings from the phase 2 LITESPARK-003 study of belzutifan in combination with cabozantinib for patients with advanced clear cell renal cell carcinoma.

Patient and Disease Characteristics Serve as Key Factors Behind Treatment Considerations in Advanced RCC

October 26th 2023

Vitaly Margulis, MD, expands on the factors to consider when treating patients with advanced RCC and how these could help inform the selection of immunotherapy-based combinations in the frontline setting.

Updated Data Continue to Aid IO-Based Frontline Treatment Decisions in Advanced RCC

October 24th 2023

Tian Zhang, MD, MHS, details how updated data presented at the 2023 ASCO Annual Meeting from trials such as KEYNOTE-426 and CLEAR have showed the sustained efficacy of VEGF plus immunotherapy combinations vs sunitinib in the first-line setting; discusses where the immunotherapy-only combination of ipilimumab and nivolumab fits in the frontline setting; and highlights how data from CONTACT-03 provided key insights on the use of immunotherapy in patients with advanced renal cell carcinoma after progression on a prior immune checkpoint inhibitor.

Retrospective Data Show Nephrectomy With Immune-Targeted Therapy Offers Potential PFS Benefit in Metastatic RCC

October 24th 2023

Nephrectomy with immune-targeted therapy was associated with a progression-free survival benefit compared with immunotherapy alone in patients with metastatic renal cell carcinoma.

Lenvatinib/Pembrolizumab Combo Elicits Durable Responses in Advanced ccRCC

October 23rd 2023

Lenvatinib in combination with pembrolizumab led to tumor shrinkage and duration of response benefits compared with sunitinib across subgroups of interest in patients with advanced clear cell renal cell carcinoma.